Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included p...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyropoulos, Alex C., Hartaigh, Bríain Ó, Cao, Zhun, Caberwal, Harjeet, Lipkin, Craig, Petrini, Michaela, Wang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272054/
https://www.ncbi.nlm.nih.gov/pubmed/35792949
http://dx.doi.org/10.1177/10760296221110568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272054/
https://www.ncbi.nlm.nih.gov/pubmed/35792949
http://dx.doi.org/10.1177/10760296221110568

Ejemplares similares